SYBX

What one share of Synlogic holds

Pharmaceutical Preparations

We are a biopharmaceutical company that previously advanced novel therapeutics to transform the care of serious diseases. We focused on rare metabolic disorders, with our lead program, labafenogene marselecobac (SYNB1934), studied in Synpheny-3, a global, pivotal Phase 3 study for patients with phenylketonuria (PKU), and SYNB1353, a potential treatment for homocystinuria (HCU).

Synlogic’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.

Per-share figures
Sales$0.00
Profit−$0.05
Cash and investments$1.13
Book value$1.03

Per share by fiscal year

YearSalesProfitCapexFree cashDividendsBook value
2017—−$90.06$5.75−$75.02——
2018—−$30.42$3.55−$30.23—$73.28
2019—−$25.45$0.62−$38.00—$72.94
2020—−$24.77$0.17−$16.72—$45.23
2021—−$16.42$0.18−$14.34—$31.69
2022—−$13.83$0.15−$12.05—$18.57
2023—−$9.42$0.03−$7.97—$3.57
2024$0.00−$1.92$0.00−$2.60—$1.09
2025$0.00−$0.08$0.00−$0.35—$1.01

Common questions about Synlogic

How much does one share of Synlogic earn?

Over the last 12 months, Synlogic lost $0.05 for each share.

Does Synlogic pay a dividend?

Synlogic didn’t pay a dividend over the last 12 months, according to its SEC filings.

What is Synlogic’s book value per share?

Synlogic’s book value is $1.03 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.

How much cash and debt does each share of Synlogic have?

Each share of Synlogic has $1.13 of cash and investments, as of June 30, 2026.

Has Synlogic bought back shares?

Synlogic’s share count rose about 2646% from 2017 to 2025. That dilution means each share owns a smaller slice of the company.

From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.